Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01460602 |
Recruitment Status :
Withdrawn
(Investigator has relocated to MD Anderson)
First Posted : October 27, 2011
Last Update Posted : September 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Follicular Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma | Drug: MTD of Velcade, Nipent and Rituxan established in Part 1 | Phase 1 Phase 2 |
Number of Subjects: During the Phase 1 part of the study as many as 15 subjects may be enrolled, based on the dose escalation scheme; the actual number of subjects enrolled will depend on the dose level at which the maximum tolerated dose (MTD) is established.
During the Phase 2 part of the study, approximately 15 subjects will be enrolled in order to obtain a total 30 response-evaluable subjects.
Study Objectives:
The primary objectives of this study are:
• Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy.
The secondary objectives of this study are to:
- Determine the MTD of VELCADE and Nipent in combination with Rituxan (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy
- Evaluate the safety and tolerability of VNR
- Determine the time to response
- Determine duration of response
- Determine the time to progression (TTP)
- Determine the progression free survival (PFS) rate
- Determine the 1-year survival
- Determine overall survival (OS)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma |
Actual Study Start Date : | May 2010 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Part 1: establish MTD
Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
|
Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
One of the following dose levels will be chosen and used in Part 2:
|
Experimental: Part 2: The MTD from Part 1
During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
|
Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
One of the following dose levels will be chosen and used in Part 2:
|
- CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48
- ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48
- Maximum Tolerated Dose [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]Number of participants with adverse events as a measure of safety and tolerability
- Rate of progression of disease [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]Summary data on time to progression of disease of study subjects

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Voluntary written informed consent.
- Male or female subject 18 years of age and older
- Karnofsky Performance Status (KPS) score of 50%. ECOG Performance Status score greater than 2.
- Histologically confirmed follicular Grade 1-3a, marginal zone or mantle cell NHL.
- Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.
- Bi-dimensionally measurable disease with at least 1 lesion 2 cm in a single dimension
- Hematologic, hepatic, and renal function parameters.
- Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs
- Expected survival of 3 months
- Accepted birth control methods during treatment and for 12 months after completion of treatment.
Exclusion Criteria:
- Follicular lymphoma Grade 3b
- History of allergy to any of the study medications, their analogues, murine proteins, or excipients in the various formulations
- Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment
- Serum creatinine 2.5 mg/dL within 14 days before enrollment.
- Absolute neutrophil count (ANC) < 1,000/L, platelet count < 70,000/L within 14 days before enrollment
- Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT/SGPT]) > 2 x the upper limit of normal (ULN), total bilirubin > 3 ULN
- Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6 months)
- Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosurea or mytomycin-C)
- Prior lymphoma vaccine therapy within 12 months to Study Day 1
- Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1
- Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1
- Known history of hepatitis or hepatic disease.
- Presence of central nervous system (CNS) lymphoma
- Known history of HIV infection or AIDS
- Histologic transformation (Follicular or Marginal zone to diffuse large B cell lymphoma [DLBCL]
- Presence of pleural or peritoneal effusion with positive cytology for lymphoma
- Another primary malignancy requiring active treatment
- Serious non-malignant disease (e.g., congestive heart failure [CHF], hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions (including psychiatric), which would compromise protocol objectives n the opinion of the Investigator and/or Sponsor
- New York Heart Association Class III or IV (Appendix D) cardiac disease
- Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
- Female subject who is pregnant or currently breast-feeding
- Received other investigational drugs with 14 days before enrollment
- Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460602
United States, Louisiana | |
LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center | |
Shreveport, Louisiana, United States, 71103 |
Principal Investigator: | Francesco Turturro, MD | LSUHSC-S |
Responsible Party: | Glenn Mills, Professor of Medicine, Louisiana State University Health Sciences Center Shreveport |
ClinicalTrials.gov Identifier: | NCT01460602 |
Other Study ID Numbers: |
X05266 |
First Posted: | October 27, 2011 Key Record Dates |
Last Update Posted: | September 1, 2020 |
Last Verified: | July 2020 |
Lymphoma Follicular Marginal Zone Mantle Cell Velcade bortezomib |
Nipent pentastatin Rituxan rituximab Turturro Shreveport |
Lymphoma Lymphoma, Mantle-Cell Lymphoma, B-Cell, Marginal Zone Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Lymphoma, Non-Hodgkin Lymphoma, B-Cell Rituximab Bortezomib Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |